SecBot SecBot
DEFA14A ·Filed Apr 24, 2026

TRDA

Entrada Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed6mo ago SEC0001689375-26-000022
Proxy solicitation materials
Actionable Insight • Neutral

This is a routine annual meeting filing with no surprises. Monitor for the outcome of the shareholder vote, but expect no immediate market impact.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$12.63
T+0 close · Apr 24, 2026 · via day close
Latest settled
−48.85%
T+60 · $6.46
Vs SPY
−53.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 24 $12.63entry
  2. T+1 · 7mo ago +2.61%α +2.45% · $12.96
  3. T+5 · 7mo ago +6.89%α +5.98% · $13.50
  4. T+20 · 6mo ago −50.04%α −54.07% · $6.31
  5. T+60 · 4mo ago −48.85%α −53.93% · $6.46
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Entrada Therapeutics is holding a shareholder meeting to vote on the election of directors, approval of the 2025 annual compensation program, and ratification of auditors. The filing is a definitive additional materials document, which is routine for an annual meeting.

Key Financial Metrics

Vote
director election
Meeting
2026-04-24

Key Facts

  • Filing is a Definitive Additional Materials (DEFA14A) for an annual shareholder meeting.
  • Vote includes election of directors, approval of 2025 annual compensation program, and ratification of auditors.
  • No activist campaign or dissident filing; this is a routine management filing.
  • Recent insider activity shows minimal selling ($32K over 30 days).

Financial Impact

Minimal to no direct financial impact from this filing.

revenueepsdebtdilution

Risk Factors

  • Potential shareholder dissent on executive compensation (though not indicated in this filing).
  • Regulatory or compliance risk if auditors are not ratified.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001689375-26-000022
Document: 0001689375-26-000022-index-headers.html0001689375-26-000022
Document: 0001689375-26-000022-index.html0001689375-26-000022
Document: 0001689375-26-000022.txt0001689375-26-000022

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026